Ticker Details
Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
IPO Date:	April 28, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$93.5M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 3.32%
Avg Daily Range (30 D):	$0.04 | 2.61%
Avg Daily Range (90 D):	$0.12 | 3.94%

Institutional Daily Volume
Avg Daily Volume:	.57M
Avg Daily Volume (30 D):	1.02M
Avg Daily Volume (90 D):	2.26M

Trade Size
Avg Trade Size (Sh.):	146
Avg Trade Size (Sh.) (30 D):	182
Avg Trade Size (Sh.) (90 D):	188

Institutional Trades
Total Institutional Trades:	448
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$.58M
Avg Institutional Trade (90 D):	$.62M
Avg Institutional Trade Volume:	.23M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.89M
Avg Closing Trade (30 D):	$.58M
Avg Closing Trade (90 D):	$.62M
Avg Closing Volume:	254.18K

News

May 25, 2026 @ 12:34 AM מועד אחרון לת... Source: Rosen Law Firm

May 25, 2026 @ 12:34 AM ALDX FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUN... Source: Rosen Law Firm

May 20, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Th... Source: Bronstein, Gewirtz & Grossman Llc

May 20, 2026 @ 12:00 PM Lead Plaintiff Deadlines in Shareholder Class Acti... Source: Holzer & Holzer, Llc

May 18, 2026 @ 10:45 PM ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldey... Source: Rosen Law Firm

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.45	$-.06	$-.1
Diluted EPS	$-.45	$-.06	$-.1
Revenue
Gross Profit
Net Income / Loss	$-27.37M	$-3.45M	$-6.46M
Operating Income / Loss	$-28.38M	$-3.55M	$-6.67M
Cost of Revenue
Net Cash Flow	$19.69M	$M	$10.7M
PE Ratio